Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Olsalazine in ankylosing spondylitis: a pilot study

C M Chapman¹, S H Zwillich

¹Department of Medicine, University of Rochester School of Medicine, NY 14642.

The Journal of Rheumatology

|September 1, 1994

Summary

Olsalazine shows promise for treating ankylosing spondylitis (AS) in men unresponsive to standard therapies. The drug demonstrated good tolerability and efficacy, with improvements in pain and joint assessments observed in most participants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Same author

Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy.

Leukemia·2013

Same author

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

Annals of the rheumatic diseases·2009

Same author

Polymorphisms in the angiotensinogen gene are associated with carotid intimal-medial thickening in females from a community-based population.

Atherosclerosis·2001

Same author

A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity.

European journal of endocrinology·2001

Same author

Multifocal Staphylococcus aureus infection originating from the sacroiliac joint in a patient with rheumatoid arthritis.

The Journal of rheumatology·2001

Area of Science:

Rheumatology
Pharmacology

Background:

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine.
Nonsteroidal anti-inflammatory drugs (NSAIDs) and physiotherapy are common first-line treatments for AS.
Some patients with AS do not respond adequately to or tolerate conventional therapies.

Purpose of the Study:

To evaluate the safety and efficacy of olsalazine in male patients diagnosed with ankylosing spondylitis.
To assess olsalazine's effectiveness in individuals unresponsive to NSAIDs and physiotherapy.

Main Methods:

A cohort of four male patients with AS participated in the study.
Two patients had previously shown no response to sulfasalazine (SASP), and one patient could not tolerate SASP.
Patients received olsalazine at a dosage up to 3 grams per day for a duration of 24 weeks.

Main Results:

One patient discontinued olsalazine due to diarrhea at a dose of 1 g/day.
The remaining three patients reported improvements in global spine self-assessment (visual analog scale - VAS).
Significant improvements were noted in spinal pain (VAS), night pain, tender joint count, and enthesis score in 2-3 patients. Erythrocyte sedimentation rate and C-reactive protein levels remained normal. Loose stools were the sole adverse effect reported.

Conclusions:

Olsalazine appears to be a well-tolerated and effective treatment option for men suffering from ankylosing spondylitis.
Further research, including direct comparisons with sulfasalazine (SASP), is warranted to elucidate olsalazine's mechanisms of action and therapeutic potential in AS.

Related Experiment Videos